SG Americas Securities LLC purchased a new stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 7,331 shares of the biopharmaceutical company’s stock, valued at approximately $151,000.
Several other institutional investors have also added to or reduced their stakes in CRBP. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at approximately $976,000. Vanguard Group Inc. lifted its stake in shares of Corbus Pharmaceuticals by 143.7% in the 1st quarter. Vanguard Group Inc. now owns 437,264 shares of the biopharmaceutical company’s stock valued at $17,158,000 after purchasing an additional 257,808 shares during the last quarter. Altitude Crest Partners Inc. bought a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at approximately $4,069,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at approximately $7,554,000. Finally, Janus Henderson Group PLC bought a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at approximately $13,363,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.
Insider Activity
In related news, major shareholder Cormorant Asset Management, Lp purchased 350,000 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were acquired at an average cost of $20.01 per share, for a total transaction of $7,003,500.00. Following the acquisition, the insider now owns 2,375,000 shares of the company’s stock, valued at $47,523,750. The trade was a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.00% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Report on Corbus Pharmaceuticals
Corbus Pharmaceuticals Stock Up 0.1 %
Shares of NASDAQ CRBP opened at $16.61 on Friday. The business has a fifty day simple moving average of $37.30 and a two-hundred day simple moving average of $43.52. The firm has a market cap of $177.51 million, a PE ratio of -2.39 and a beta of 2.53. Corbus Pharmaceuticals Holdings, Inc. has a twelve month low of $3.03 and a twelve month high of $61.90.
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.29. On average, research analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -3.8 earnings per share for the current year.
Corbus Pharmaceuticals Profile
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Further Reading
- Five stocks we like better than Corbus Pharmaceuticals
- What Are Dividend Champions? How to Invest in the Champions
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- There Are Different Types of Stock To Invest In
- Tesla Stock: Buy the Dips, Sell the Rips
Want to see what other hedge funds are holding CRBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report).
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.